Showing results (701-710 of 789) with videos related to

Sort By:
Pageof 79
European Journal of Cancer (Oxford, England : 1990)|August 8, 2025
Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancerLaura L Michel, Philipp Ziegler, Philipp Kreis, et al.
Breast (Edinburgh, Scotland)|September 21, 2020
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in GermanyAndreas Schneeweiss, Johannes Ettl, Diana Lüftner, et al.
Breast (Edinburgh, Scotland)|February 14, 2025
Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancerChristina B Walter, Andreas D Hartkopf, Alexander Hein, et al.
Journal of Molecular Medicine (Berlin, Germany)|December 13, 2017
LEFTY2 inhibits endometrial receptivity by downregulating Orai1 expression and store-operated Ca<sup>2+</sup> entryMadhuri S Salker, Yogesh Singh, Ruban R Peter Durairaj, et al.
Breast (Edinburgh, Scotland)|August 25, 2011
Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trialJ Huober, P A Fasching, M Barsoum, et al.
Geburtshilfe Und Frauenheilkunde|October 3, 2022
Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients - Data from the Real-World Registry PRAEGNANTTobias Engler, Peter A Fasching, Diana Lüftner, et al.
Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin|November 30, 2010
[Are breast biopsies adequately funded? A process cost & revenue analysis]M Hahn, E Fischbach, T Fehm, et al.
Journal of Clinical Microbiology|October 26, 2018
Longitudinal Clinical Performance of the RNA-Based Aptima Human Papillomavirus (AHPV) Assay in Comparison to the DNA-Based Hybrid Capture 2 HPV Test in Two Consecutive Screening Rounds with a 6-Year Interval in GermanyThomas Iftner, Klaus-Joachim Neis, Alejandra Castanon, et al.
BMC Cancer|July 13, 2014
Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patientsMarkus Wallwiener, Sabine Riethdorf, Andreas Daniel Hartkopf, et al.
Breast Cancer Research and Treatment|October 17, 2018
Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysisPeter A Fasching, Andreas D Hartkopf, Paul Gass, et al.
Pageof 79